|Day Low/High||1.67 / 1.70|
|52 Wk Low/High||1.46 / 8.05|
These stocks look ready to break out and trade higher from current levels.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Multi-Center, Randomized, Controlled Phase 1/2 Clinical Trial in Mobilized Peripheral Blood HCT to be Initiated in Mid-2016
Proprietary Pluripotent Cell Platform for Engineered Adoptive Immunotherapies to be Highlighted During Two Poster Sessions
Proprietary Pluripotent Cell Platform Has Broad Applicability for Development of Off-the-Shelf Cancer Immunotherapies
Raymond James analyst Reni Benjamin says positive news may be ahead for these companies.
Fate Therapeutics (FATE) is developing several small molecules which modulate umbilical cord stem cells.